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Abstract
This rewiew was mad to establish the convenience of dental implant treatment in patients receiving bisphosphonates 
or programmed to receive such drugs, with a description of their mechanisms of action and the way in which they 
can affect the mandibular or maxillary bone of dental implant candidates. In turn, a description is provided of the 
key elements for evaluating the benefit-risk ratio in patients treated with bisphosphonates who require oral surgery.
Clinicians must be aware of the potential risk of osteonecrosis in patients treated with bisphosphonates via the oral 
or intravenous route.
When bisphosphonates are administered via the intravenous route, all invasive oral procedures (including implant 
surgery) are contraindicated, and should be avoided unless absolutely necessary. The indications are more controver-
sial in the case of bisphosphonates administered via the oral route. There is little literature on the influence of oral 
bisphosphonates upon bone repair, and there are not many published cases of mandibular or maxillary osteonecrosis 
among patients that receive such medication.
The use of bisphosphonates is becoming increasingly widespread, and the duration of such treatment is increasing. 
It would be of interest to design studies to evaluate the risk factors of maxillary osteonecrosis among dental implant 
patients receiving treatment with oral bisphosphonates, and to define biomarkers capable of indicating the level of 
risk in the event of oral surgery in patients receiving such drugs.
Key words: Osteonecrosis, bisphosphonates, implants, oral surgery, osteoporosis.
              Article Number: 1111111709
              © Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946 
              eMail:  medicina@medicinaoral.com 
Indexed in: 
- Science Citation Index Expanded
- Journal Citation Reports
- Index Medicus, MEDLINE, PubMed
- Excerpta Medica, Embase, SCOPUS, 
- Indice Médico Español
Introduction
Success in implant-supported restorations requires due 
evaluation of  the risk factors, with correct patient se-
lection. In this sense, there must be no local or systemic 
contraindications to implant surgery. Some absolute 
contraindications to dental implant (DI) rehabilitation 
are disease processes such as recent myocardial infarction 
or cerebrovascular stroke, heart valve surgery, immune 
suppression, blood dyscrasias, active neoplastic disease 
undergoing treatment, drug abuse, psychiatric disorders 
and, as a more recent contraindication, intravenous bis-
phosphonate (BPP) treatment (1).
BPPs are widely used for the treatment of diseases such as 
multiple myeloma, bone metastases and malignant hyper-
calcemia (2), as well as for the prevention and treatment 
of osteoporosis and other skeletal diseases such as Paget’s 
disease (2).
BPPs are endogenous pyrophosphate analogs that prove 
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comparatively more difficult to metabolize. Their mole-
cular structure comprises two phosphate groups (respon-
sible for the low bioavailability of  these drugs) bound 
to a carbon atom, and two radicals (R1 and R2), which 
are likewise bound to the central carbon atom. The R1 
radical determines affinity for binding to hydroxyapatite, 
while the R2 radical determines the potency and efficacy 
of the drug (Figure 1). Minor changes in BPP molecular 
structure in turn lead to changes in their physicochemical, 
biological, therapeutic and toxicological properties (3). 
The BPPs marketed in Spain, and their corresponding 
brand names, are indicated in Table 1.
BPPs act by fixing to bone hydroxyapatite, inhibiting bone 
reabsorption by reducing osteoclast activity, facilitating 
their apoptosis and inhibiting their production from the 
corresponding hematopoietic precursor cells. They also 
reduce osteoblast apoptosis and stimulate the secretion of 
osteoclast recruitment inhibitors. A degree of antiangio-
genic activity has also been reported as being responsible 
for some of the effects of these drugs.
BPPs are well tolerated when adequately administered, 
though different adverse effects and complications have 
been associated with their use.
In the case of oral bisphosphonates, the most common 
side effects are oral erosions, gastric ulcer, esophagitis and 
esophageal stenosis. The adverse effects of intravenous 
bisphosphonates are similar, but moreover also include 
phlebitis, transient febricula, chills, pseudoinfluenza syn-
drome in the first two days of treatment, and renal failure 
when intravenous infusion is rapid (4).
In recent years, the appearance of numerous cases of os-
teonecrosis (ON) of the maxillas of patients treated with 
BPPs has drawn considerable attention.
ON induced by bisphosphonates is characterized by the 
appearance of exposed mandibular or maxillary bone over 
a period of over 8 weeks in patients receiving or who have 
received BPPs without radiotherapy of the maxillofacial 
zone (5).
The diagnosis must be based on the clinical evidence, the 
radiological findings and the histological analysis. ON 
presents as an exposure of alveolar bone either sponta-
neously or secondary to invasive oral surgical procedures. 
Radiologically, ON can manifest as normal bone, while 
the histological findings can correspond to bone necrosis 
with bacterial colonization. A differential diagnosis must 
be established with bacterial osteomyelitis and osteora-
dionecrosis (5).
The aim of the present study is to establish the convenience 
of dental implant treatment in patients receiving bisphos-
phonates, and to define the key elements for evaluating the 
benefit-risk ratio in patients treated with bisphosphonates 
who require oral surgery.
Results
Estefania-Fresco et al. (6) conducted a review of the cases 
of ON associated to BPPs, published up until 2005, in 
which an increased appearance of ON was observed in 
women, and in particular in women over 55 years old. 
The nitrogenated BPPs developed for parenteral adminis-
tration and of high potency (pamidronate and zoledronic 
acid) were the drugs most commonly associated with ON. 
However, cases were also reported with orally administered 
BPPs (alendronate and risedronate).
There have been descriptions of ON in patients receiving 
treatment with BPPs during long periods of time, and 
also in patients subjected to such therapy for only a few 
weeks. However, different authors have correlated timing 
Fig. 1. Basic bisphosphonate chemical structure.
DRUG 
SUBSTANCE
BRAND NAME 1 ADMINISTRATION
Alendronate 2 Adrovance®, Alendrocare®, Bifoal®, Fosamax®, Fosavance® Oral
Risedronate Acrel®, Actonel®. Oral
Etidronate Difosfen® , Osteum® Oral
Clodronate Bonefos®. Oral
Tiludronate Skelid® Oral
Ibandronate Bondenza®, Bondronat®, Bonviva® Oral / intravenous
Zolendronate Aclasta®, Zometa® Intravenous
Pamidronate 2 Aredia®, Linoten®, Pamifos®. Intravenous
Table 1. Bisphosphonates marketed in Spain.
1 Brand names marketed in Spain
2 In the case of alendronate and pamidronate, generic drugs are also available that include the international nonproprietary 
name (INN) of the drug substance in the marketed name
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of the administration of BPPs to the risk of ON (7-10). 
The lesions documented have been both spontaneous 
and secondary to some type of dental treatment. Dental 
extraction was reported as the most frequent antecedent 
of ON in patients treated with BPPs via both the intra-
venous and oral routes. The possibility thus arises that 
oral surgery and DIs may be factors predisposing such 
patients to ON (6).
Many studies have addressed this subject (7-12). In the case 
of patients receiving intravenous BPPs, agreement is clear, 
and such treatment is regarded as an absolute contrain-
dication to the placement of DIs. However, controversy 
arises in the case of treatment with oral BPPs.
The Summaries of Product Characteristics of drugs such 
as Zometa® and Aredia® suggest that dental professionals 
should adhere to the following protocol when dealing with 
patients treated with intravenous BPPs:
- Clinical oral examination of oncological patients progra-
mmed to start treatment with intravenous BPPs.
- Avoidance of  invasive dental procedures during the 
period of treatment.
- Reporting of the appearance of any case of ON or of 
serious adverse effects to the company manufacturing the 
drug product, or to the competent health authorities.
Regarding the use of oral BPPs, and despite the docu-
mentation of occasional cases of ON, the United States 
Food and Drug Administration (FDA) does not advocate 
modification of the treatment plan in these patients. Howe-
ver, in the concomitant presence of other risk factors such 
as prolonged therapy, treatment with corticoids, etc., the 
patient must be warned of the possibility of ON in cases 
of surgery affecting periosteum or bone.
The Multiple Myeloma Research Foundation recommends 
that patients treated with intravenous BPPs should wear 
perfectly fitting dentures; that root canal treatment and 
fillings should be considered for the preservation of teeth, 
rather than the placement of DIs (which is considered to 
be contraindicated); and that the best treatment modality 
is prevention (9).
Scully, Madrid and Bagán (11) consider that there is no 
evidence to suggest that bone disorders are a contraindica-
tion to DIs, though there is evidence that intravenous BPP 
therapy is effectively contraindicated – since the prolonged 
use of BPPs can suppress bone remodeling capacity to 
the point where bone repair in response to trauma of any 
kind is practically abolished. Whenever possible, dental 
extractions must be avoided, as well as any kind of surgery 
oral—including the placement of DIs. Alternatively, such 
procedures should be performed before starting treatment 
with BPP. If  surgery proves absolutely necessary while the 
patient is receiving BPP treatment, due information must 
be provided of the risks, and strictly aseptic techniques 
must be used, with atraumatic surgery and healing by first 
intention whenever possible.
Different authors consider that in patients receiving 
treatment with BPPs who must undergo surgery, prior 
withdrawal of these drugs may be advisable. Nevertheless, 
there is no evidence that the suppression of such treatment 
is able to prevent the appearance of jaws ON, since the 
half-life of BPPs is very long.
Osteoporosis and osteopenia are characterized by a re-
duction in bone mass leading to skeletal fragility and an 
increased risk of bone fractures. The incidence of these 
disorders, associated to the increase in life expectancy 
in the industrialized world and to a growing number of 
pregnancies in later stages in life, is increasing conside-
rably (13).
The risk factors for osteoporosis can be divided into 
two groups: non-modifiable and modifiable. The non-
modifiable factors include variables such as sex, age, early 
menopause, small body size or thinness, and racial and 
hereditary factors. The modifiable risk factors in turn in-
clude insufficient calcium ingestion, sedentarism or a lack 
of physical exercise, smoking and alcohol abuse. Many of 
these risk factors of osteoporosis are similar to those that 
influence the failed osteointegration of DIs (14,15).
The usual treatment for osteoporosis includes calcium 
and vitamin D supplements, BPPs  (oral or intravenous), 
selective estrogen receptor modulators (SERMs; funda-
mentally raloxifen and tamoxifen), calcitonin, teriparatide 
and hormone replacement therapy (HRT). Of all these 
treatment options, only oral BPPs have been shown by 
randomized, long-term studies to reduce the risk of hip 
fractures (15).
Osteoporosis is not a major health risk, though its 
treatment is important for patient quality of  life. The 
prevention and treatment of osteoporosis are important 
aspects to be taken into account in patients programmed 
for the placement of DIs (15,16).
The demand for DIs has increased enormously in recent 
years. A large percentage of  the population requiring 
treatment with DIs are elderly persons over 65 years of 
age in which osteoporosis is very common (5,17). This 
increased demand for the placement of DIs in osteoporotic 
patients treated with BPPs makes necessary for dental 
professionals to improve their knowledge of this disease, 
its treatment, and the effects of BPPs upon DI surgery.
Histological studies in humans show that osteoporotic 
bone suffers a decrease in mechanical resistance, with 
alterations of the trabecular structure, a lessened mineral 
content, and an increase in crystallization and in the car-
bonate/phosphate ratio. The influence of these changes 
in relation to the success of DI surgery is not fully clear. 
A number of studies involving patients with osteoporosis 
have reported a discrete effect of this disease upon the 
success of DI. In this sense, Friberg et al. (18) placed 70 
DIs in 14 osteoporotic patients, with a success rate of over 
97% after three years in both the maxillary and in the 
mandibular region. This study suggests that osteoporosis 
in itself  does not affect the outcome of DI surgery.
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Minsk and Polson (19) analyzed a total of 450 maxillary 
and mandibular DIs placed in 116 postmenopausal women 
over 50 years of age. The objective of the study was to 
determine whether hormone replacement therapy reduces 
the risk of DI failure in postmenopausal women, though 
the results obtained did not support this hypothesis.
August et al. (20) found that mandibular DI failure 
occurs with equal frequency in postmenopausal and pre-
menopausal patients. In contrast, the postmenopausal 
patients showed a greater percentage failure of maxillary 
implants.
Although these studies do not mention the degree of 
osteoporosis in the patients, osteoporosis was assumed 
to imply a high risk of DI failure.
Studies have been made in experimental models of pe-
riodontitis induced in animals treated with BPPs, with 
beneficial effects. Two studies showed low oral doses of 
these drugs to be beneficial, and defined an optimum dose 
for the treatment of  periodontitis in monkeys (21,22). 
Likewise, different human studies have shown a positive 
effect of BPPs in the management of periodontal disease 
progression (23-25).
Chacon et al. (17) published an in vivo study in rabbits de-
signed to explore the effects of the systemic administration 
of alendronate upon DI osteointegration, based on the 
torque values required to remove the implants. Identical 
titanium DIs were placed bilaterally in the femur and tibia 
of 20 white New Zealand rabbits, using a standardized 
surgical protocol. One week after surgery, 10 of the 20 
rabbits received alendronate during 5 weeks. The torque 
values required to remove the DIs were determined using 
a Tohinichi 15-BTG torque Wrench®. The data analysis 
showed no statistically significant difference between the 
group treated with alendronate and the control group. 
The authors concluded that the oral administration of 
alendronate in rabbits exerts no significant effects upon 
the torque needed to remove the DIs six weeks after their 
placement in the tibia and femur. They also reported the 
absence of ON, though they pointed out that the surgical 
beds were not exposed to the oral cavity, and that the con-
ditions were different to those found in clinical practice. 
The cases of ON in patients treated with oral BPPs have 
been documented in maxillary and mandibular bone. 
The effects of  BPPs upon bone are probably location-
dependent (maxillas), and are influenced by local factors 
(irritative and infectious).
Altundal et al. (27) conducted a study in albino rats with 
the purpose of  determining the effects of  alendronate 
upon the reabsorption of alveolar bone following tooth 
extraction. The maintenance of  alveolar bone both in 
height and in volume following the loss of  a tooth is 
essential for successful DI restoration surgery, and it is 
well known that alendronate is a potent inhibitor of bone 
reabsorption mediated by osteoclasts. The study concluded 
that in the alendronate treatment group, the reduction 
in alveolar bone volume (both buccal and lingual) was 
significantly lower than in the group treated with saline 
solution. Likewise, an important reduction was observed 
in the calcium levels in serum and urine, and the number 
of osteoclasts revealed marked suppression of bone reab-
sorption in the group treated with alendronate.
Denissen et al. (28) considered the possibility of applying 
BPPs locally to improve the quality, osteoconduction 
and repair of alveolar bone. In different studies, hydrox-
yapatite DIs have been used in an attempt to maintain 
alveolar bone following tooth extraction. However, the 
clinical results have shown that hydroxyapatite requires 
the introduction of a modification to increase its efficacy. 
The authors therefore combined the implants with a bone 
reabsorption inhibitor in the form of BPPs. This study 
contributes to improve our understanding of the proper-
ties of hydroxyapatite DIs as transporters or supports for 
BPPs, which in turn would act as bone modeling agents. 
The results obtained suggest that osteoconduction and 
the repair of alveolar bone around the hydroxyapatite-
bisphosphonate complex prove normal.
Jeffcoat (16) carried out two controlled studies with the 
purpose of demonstrating the safety of oral BPPs in pa-
tients with periodontitis and in patients subjected to oral 
surgery. The first was a double-blind, placebo-controlled 
trial designed to demonstrate both the efficacy and the 
safety of  oral alendronate at a dose of  70 mg weekly, 
administered for 11 weeks to patients with moderate 
or severe periodontal disease. A significant benefit was 
recorded in terms of  alveolar bone height (ABH), de-
fined as the distance between the amelocemental limit 
and the alveolar crest, in the patients treated with oral 
alendronate and belonging to the low mandibular bone 
mineral density group, compared with placebo. However, 
the difference was not significant in the group of patients 
with normal bone mineral density values. In no case was 
jaws ON seen during the two years of follow-up, and the 
number of teeth lost in the treated group was lower than 
in the placebo group.
The second study was a parallel-group controlled trial 
involving patients subjected to DI treatment who had 
received oral BPPs versus patients with DI who had not 
received BPPs. All the patients were postmenopausal wo-
men with osteoporosis. The patients of the treated group 
had received BPPs between 1-4 years prior to inclusion 
in the study. The analysis of the results showed that after 
three years of follow-up, a full 100% of the DIs placed in 
the BPP-treated patients were successful, compared with 
99.2% of those in the control group – though the difference 
between the two groups was not statistically significant. 
The author concluded that the decision to introduce some 
medical or dental treatment, such as the prescription of 
oral BPPs or the placement of DIs, requires evaluation of 
the associated benefit-risk ratio.
Osteoporosis is a serious condition that undoubtedly re-
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quires treatment in the absence of major risk factors. In 
the two studies commented above, no evidence was found 
to suggest that oral BPPs constitute a risk for alveolar 
bone ON versus placebo.
Other investigators (29,30) have reported that oral alen-
dronate improves alveolar bone thickness and density at 
a dose of 70 mg a week. However, the duration of the 
studies was limited to 6 months; as a result, it cannot be 
confirmed that the effect persists over the long term.
Very recently, Grant et al. (12) have published the results 
of the review of 468 implants placed in 115 patients that 
had been treated with oral BPPs for different disorders. 
There were no cases of maxillary ON among the reviewed 
patients, though the authors concluded that there is suffi-
cient evidence to suggest that all patients programmed 
for DI surgery should be questioned about BPP therapy 
– including the type of drug, the dose, and the duration 
of treatment.
Furthermore, it should be considered that all patients 
administered BPPs for more than three years with con-
comitant prednisone therapy are at an increased risk of 
developing ON. As a result, other noninvasive treatment 
options should be proposed in such patients (12)
Discussion
The placement of dental implants (DIs) induces a series 
of metabolic changes around the implants that should 
lead to the formation of bone intrinsically bound to the 
implant surface. If the bone surrounding the DI presents a 
medium to high concentration of bisphosphonates (BPPs), 
these turnover and remodeling processes will be hindered 
or prevented – with the risk of necrosis of the surrounding 
bone. The situation is different in the case of  patients 
receiving BPPs who have already undergone DI surgery 
previously. In this context, it is before starting treatment 
with BPPs when all the dental procedures necessary for 
adequate oral health should be provided, with a view to 
avoiding problems at a later point in time (31).
Clinicians must be aware of the potential risk of osteo-
necrosis (ON) in patients treated with BPPs via the oral 
or intravenous route. All the articles consulted in the 
literature agree that in patients treated with intravenous 
BPPs, it is necessary to avoid any kind of invasive oral 
procedure (such as DI placement), unless such techniques 
are considered absolutely necessary.
If  the patient is programmed to receive BPPs, the dental 
professional must carry out a correct oral exploration 
to ensure that all teeth amenable to extraction are dealt 
with before the start of BPP therapy (31). Regarding the 
placement of DIs in patients receiving intravenous therapy 
with these drugs, very few data are available to date. Mo-
reover, the risk of postoperative maxillary ON following 
the cessation of intravenous therapy with BPPs remains 
uncertain. In recent years, as a result of the appearance of 
numerous reports of maxillary ON exhibiting a presumed 
time-dependent relationship, oncologists and pharmacists 
have begun to debate the time for which intravenous 
therapy with BPP must be maintained. In this sense, it 
seems that beyond a period of two years, the efficacy of 
such therapy does not improve, though the risk of adverse 
effects increases (10,13).
The principal discussion arises when BPP treatment is 
administered via the oral route. To date, the literature 
offers very little information on the influence of  oral 
BPPs upon bone repair, and there are not many published 
cases of mandibular or maxillary ON in patients receiving 
treatment of this kind. The American Dental Association 
suggests no modification in the oral BPP treatment plan 
when contemplating invasive oral procedures – though if  
there are other risk factors such as the prolonged use of 
such drugs, concomitant estrogen or corticoid treatment, 
or advanced age, the patient must be informed of the po-
tential complications. The number of patients receiving 
treatment with BPPs is increasing, and the duration of 
such treatment is also being prolonged. Dental profes-
sionals and oral surgeons therefore must be aware that 
there is a potential risk of ON with the prolonged use 
of BPP that in turn can be increased by the introduction 
of invasive procedures such as DI surgery. It would be 
interesting to conduct further controlled clinical studies 
to assess treatment with oral BPPs and the appearance of 
maxillary ON, with a view to establishing clearer guidelines 
for the treatment of these patients.
Current evidence suggests the avoidance of dental implant 
procedures in patients that have been receiving intravenous 
BPPs. In the case of administration via the oral route, cau-
tion is required – avoiding these procedures, or indicating 
them only when absolutely necessary.
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